Tech Company Financing Transactions
Surrozen Funding Round
On 3/15/2019, Surrozen raised $50 million in Series B investment from Hartford HealthCare, Horizons Ventures and NS Investment.
Transaction Overview
Company Name
Announced On
3/15/2019
Transaction Type
Venture Equity
Amount
$50,000,000
Round
Series B
Investors
Proceeds Purpose
Proceeds from the financing will be used to advance the Company's antibody discovery and development programs in liver disease, and to expand the Company's therapeutic platform into additional disease areas where Wnt modulation has therapeutic potential.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
171 Oyster Point Blvd. 400
South San Francisco, CA 94080
USA
South San Francisco, CA 94080
USA
Phone
Website
Email Address
Overview
Surrozen Inc. is a biopharmaceutical company focused on harnessing the Wnt pathway for applications in regenerative medicine. Founded on breakthrough science from Stanford University and backed by The Column Group, Surrozen is implementing a surrogate Wnt platform with the potential to unlock stem cell control in a wide array of human tissues.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chairman
Timothy Kutzkey
Chief Executive Officer
Craig Parker
Chief Medical Officer
Trudy Vanhove
Chief Scientific Officer
Wen-Chen Yeh
Vice President
Yang Li
VP - Bus. Development
Reza Afkhami
VP - General Counsel
Sheela Peterson
VP - Human Resources
Christine McKinley
Browse more venture capital transactions:
Prev: 3/15/2019: ProdPerfect venture capital transaction
Next: 3/15/2019: Capital Markets Gateway venture capital transaction
Share this article
Where The Data Comes From
We report on tech company VC transactions. VC investment data records on this site are sourced from a variety of public sources. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs